

Date: 12th November, 2025

To,
Department of Corporate Services,
BSE Limited,
P. J. Towers, Dalal Street Fort,
Mumbai - 400 001.

BSE Scrip Code:524604

Sub.: Outcome of Meeting of Board of Directors held today i.e. 12.11.2025

Respected Sir/Madam,

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") this is to inform you that the Board of Directors of the Company at its Meeting held today, i.e., on Wednesday, 12th day of November, 2025 (which commenced at 05:45 p.m. and concluded at 06:05 p.m. inter alia, has approved/noted the following: -

- 1. Approval of the Unaudited Standalone Financial Results for the Quarter and Half Year Ended September 30, 2025.**
Upon recommendation of the Audit Committee, the Board of Directors has approved the Unaudited Standalone Financial Result as per Indian Accounting Standards (IND AS) for the Quarter and half year ended September 30, 2025 (enclosed herewith).
- 2. Noting of the Limited Review Report of the Statutory Auditors on the Unaudited Standalone Financial Results for the Quarter and Half Year Ended September 30, 2025.**
The Limited Review Report of the Statutory Auditors for the Quarter and half year ended September 30, 2025. The Board of Directors took note of the same (enclosed herewith).
- 3. Taken on Record the resignation received from the Mr. Sarang Pathak (DIN: 02663344) from the post of Executive Director – Chairman (Managing Director) and Mr. Hemant Parikh (DIN: 00027820) from the post of Non-Executive - Promoter Director with effect from the closing of the Business hours on 12th November, 2025.**
- 4. Appointed and designated Mr. Vrushank Patel (DIN: 05125502) - Executive Director of the Company as Chairman of the Board and the Company w.e.f. 12th November, 2025, with a view to ensuring continuity in leadership and the sustained growth of the organization.**
- 5. Authorised Mr. Vrushank Patel (DIN: 05125502), Executive Director of the Company to sign /authenticate all the necessary applications, papers and documents required to be submitted to the various authorities for various approval and to do all such acts and deeds for the smooth functioning of the management of the Company and to delegate the powers for the same.**
- 6. Noting of SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2025/97 dated July 2, 2025:**

ADLINE CHEM LAB LIMITED

CIN: L35106GJ1988PLC010956



ADLINE

ADLINE CHEM LAB LIMITED
The SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2025/97 dated July 2, 2025 issued under the Ease of Doing Investments initiative, providing a Special Window for Re-lodgement of Transfer Requests of Physical Shares was place before the Board of Directors. The Board took the note of the same and instructed to take necessary steps with regard to the same.

We request you to please take the above information on your records.

Thanking you,

Yours sincerely,

For, Adline Chem Lab Limited



Sarang Bharatbhai Pathak*

Managing Director

DIN: 02663344

ADLINE CHEM LAB LIMITED

CIN: L35106GJ1988PLC010956

(Formerly Kamron Laboratories Limited)

The Board of Directors**ADLINE CHEMLAB LIMITED****Independent Limited Review Report on the quarterly unaudited Standalone Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

1. We have reviewed the accompanying statement of unaudited financial results of Adline Chem Lab Ltd. (the "Company") for the quarter ended September 30, 2025 which include financial results ended on that date together with the relevant notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Regulations, 2015"). The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. This Statement, which is the responsibility of the Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with applicable Indian Accounting Standard ('Ind AS') and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Jain Kedia & Sharma
Chartered Accountants
FRN: 103920W



Tarak
Tarak Shah
Partner

Place: Ahmedabad

Date: November 12, 2025

Membership No. 182100

UDIN: 25182100BMODDD7343

<p style="text-align: center;">ADLINE CHEM LAB LIMITED Regd. Office: 401, Karthik 2, Opp. Rajpaw Club, S. G. Highway, Ahmedabad 380054 CIN : L28231GJ1989PLC019916 Ph.no: 079 26870952/54 Email id: secretariat.adlinechemlab@gmail.com Website : www.adlinechem.com</p> <p style="text-align: center;">STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th September, 2025</p> <p style="text-align: right;">(Rs in Lakhs)</p>						
Particulars	Quarter Ended			Half Year Ended		Year Ended
	30th Sep 2025	30th June 2025	30th Sep 2024	30th Sep 2025	30th Sep 2024	31st Mar 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	-	-	-	-	-	-
Other Income	-	-	-	-	-	24.89
Total Income	-	-	-	-	-	24.89
Expenses						
Cost of materials consumed	-	-	-	-	-	-
Purchase of Stock in Trade	-	-	-	-	-	-
Change in inventories of finished goods, Stock-in-Trade and work-in-progress	-	-	-	-	-	-
Employee benefits expense	0.18	0.81	4.71	0.99	8.33	17.64
Finance costs	2.87	2.77	3.39	5.65	6.70	13.12
Depreciation and amortization expense	-	-	-	-	-	-
Other expenses	4.97	2.29	2.02	7.26	8.57	14.70
Total expenses	8.02	5.87	10.13	13.89	23.60	45.46
Profit/(loss) before exceptional items and tax	(8.02)	(5.87)	(10.13)	(13.89)	(23.60)	(20.57)
Exceptional items	-	-	-	-	-	-
Profit/(loss) before tax	(8.02)	(5.87)	(10.13)	(13.89)	(23.60)	(20.57)
Tax expense:	(0.76)	(0.74)	(0.86)	(1.50)	(1.70)	(7.35)
Current tax	-	-	-	-	-	-
Prior period tax	-	-	-	-	-	2.78
Deferred tax	(0.76)	(0.74)	(0.86)	(1.50)	(1.70)	(10.13)
Profit (Loss) for the period from continuing operations	(7.26)	(5.13)	(9.27)	(12.39)	(21.90)	(13.22)
Profit/(loss) from discontinued operations	-	-	-	-	-	-
Tax expense of discontinued operations	-	-	-	-	-	-
Profit/(loss) from Discontinued operations (after tax)	-	-	-	-	-	-
Profit/(loss) for the period	(7.26)	(5.13)	(9.27)	(12.39)	(21.90)	(13.22)
Other Comprehensive Income	0.15	0.15	0.46	0.30	0.92	1.10
Items that will not be reclassified to profit or loss (Net of tax)	0.15	0.15	0.46	0.30	0.92	1.10
Benefit due to actuarial valuation of gratuity	0.20	0.20	0.61	0.40	1.22	1.46
Deferred tax	(0.05)	(0.05)	(0.15)	(0.10)	(0.31)	(0.37)
Items that will be reclassified to profit or loss (Net of tax)	-	-	-	-	-	-
Total Comprehensive Income for the period	(7.11)	(4.98)	(8.81)	(12.09)	(20.98)	(12.13)
Paid-up equity share capital (Face Value of the Share Rs. 10/- each)	585.00	585.00	585.00	585.00	585.00	585.00
Earnings per equity share (for continuing operation):						
Basic	(0.01)	(0.01)	(0.02)	(0.04)	(0.04)	(0.02)
Diluted	(0.01)	(0.01)	(0.02)	(0.04)	(0.04)	(0.02)
Earnings per equity share (for discontinued operation):						
Basic	(0.01)	(0.01)	(0.02)	(0.04)	(0.04)	(0.02)
Diluted	(0.01)	(0.01)	(0.02)	(0.04)	(0.04)	(0.02)
Earnings per equity share (for continuing & discontinued operation):						
Basic	(0.01)	(0.01)	(0.02)	(0.04)	(0.04)	(0.02)
Diluted	(0.01)	(0.01)	(0.02)	(0.04)	(0.04)	(0.02)

Notes :

1. This statement has been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 Accounting Standards Rules, 2015 (as amended). The statutory auditors of the company have carried out limited review of the financial results for the quarter ended September 30, 2025.

2. These results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on November 12, 2025, and approved by the Board of Directors at its meeting held on November 12, 2025. The Statutory Auditors Report does not have any qualification / modification.

3. EPS is not annualized for the quarter ended September 30, 2025, June 30, 2025 and September 30, 2024 and for the half year ended September 30, 2025 and September 30, 2024.

Place: Ahmedabad
Date : November 12, 2025

For, Adline Chem Lab Limited


Sarang Pathak
Managing Director
DIN : 02663344




**STANDALONE UNAUDITED STATEMENT OF ASSETS & LIABILITIES AS AT
SEPTEMBER 30, 2025**

Particulars	(Rs in Lakhs)	
	As at 30th September 2025	As at 31st March 2025
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	-	-
(b) Capital work-in-progress	-	-
(c) Investment Property	-	-
(d) Goodwill	-	-
(e) Other Intangible assets	-	-
(f) Intangible assets under development	-	-
(g) Biological Assets other than bearer plants	-	-
(h) Financial Assets		
(i) Investments	-	-
(ii) Trade receivables	-	-
(iii) Loans	-	-
(iv) Others (to be specified)	-	-
(i) Deferred Tax Assets	-	-
(j) Other non current assets	-	0.64
Current assets		
(a) Inventories	-	-
(b) Financial Assets		
(i) Investments	-	-
(ii) Trade Receivable	-	-
(iii) Cash and cash equivalents	7.36	6.32
(iv) Bank balances other than (iii) above	-	-
(v) Loans	-	-
(vi) Short Term Loans & Advances	4.52	-
(c) Current Tax Assets (Net)	-	-
(d) Other current assets	-	0.59
TOTAL ASSETS	11.89	7.55
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	585.00	585.00
(b) Other Equity	(746.41)	(734.33)
Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	164.95	148.78
(i.a) Lease Liabilities	-	-
(ii) Trade payables	-	-
(iii) Other financial liabilities	-	-
(b) Provisions	-	0.62
(c) Deferred tax liabilities (Net)	4.52	5.92
(d) Other non-current liabilities	-	-
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(i.a) Lease Liability	-	-
(ii) Trade payables	1.57	-
(iii) Other financial liabilities [other than those specified in item (c)]	-	-
(b) Other current liabilities	0.66	-
(c) Provisions	1.60	1.55
(d) Current Tax Liabilities (Net)	-	-
TOTAL EQUITY AND LIABILITIES	11.89	7.55

Place: Ahmedabad
Date : November 12, 2025

For, Adline Chem Lab Limited


Sarang Pathak
Managing Director
DIN : 02663344



ADLINE CHEMLAB LIMITED

standalone statement of Cash flow for the Half year ended September 30,2025

Particulars	For the Half Year ended September 30,2025	For the Half Year ended March 31,2025
Cash flow from operating activities		
1. Profit before tax	(13.89)	(20.57)
	(13.89)	(20.57)
2. Adjustment for :		
Depreciation and amortisation expense	-	-
Finance cost	5.65	13.12
Provision for Gratuity	-	1.46
Remasurement Benefit due to gratuity	0.40	(24.89)
Changes due to Modification in Financial Liabilities	-	
	(7.84)	(30.87)
Operating profit before working capital changes (1+2)		
3. Adjustments for working capital changes:		
Decrease / (Increase) in Trade and other receivables	2.23	-
(Decrease) / Increase in Trade and other payables	-	-
Decrease /(Increase) in Inventory	-	0.19
Increase / (Decrease) in other current liabilities	0.04	(0.83)
Increase / (Decrease) in provisions	(3.93)	(1.23)
(Increase)/Decrease in other current assets		
	(9.50)	(32.74)
Cash used in operations		
Extraordinary item		
4. Direct taxes paid		10.13
Income Tax Paid / Income Tax Refund (Net)	-	-
	(9.50)	(22.61)
Net Cash generated from/(used in) operating activities [A]		
Cash Flow from investing activities		
Purchase of fixed assets (including capital advances) (Net of CWIP trf)	-	-
Proceeds from sale of fixed assets	-	-
Share income (loss) from partnership firm	-	-
(Purchase) / Proceeds of non-current investments (Net)	-	-
Proceeds from Loans and Advances (Net)	-	-
Interest received	-	-
Net cash generated from/(used in) investing activities [B]		
Cash flow from financing activities		
Proceeds from long term borrowings, net		-
Proceeds from short term borrowings, net		-
Finance cost	(5.65)	(13.12)
Increase /(Decrease) in Borrowings (Liabilities)	16.18	37.83
	10.53	24.71
Net cash generated from/(used in) financing activities [C]		
Net increase/(decrease) in cash & cash equivalents [A+B+C]	1.04	2.10
Cash & cash equivalents at the beginning of the year	6.32	4.22
Cash & cash equivalents at the end of the year	7.36	6.32
Cash & cash equivalents	7.36	6.32

For, Adline Chem Lab Limited

Place: Ahmedabad

Date : November 12, 2025

Sarang Pathak
Managing Director
DIN : 02663344

